Lamotrigine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:420280917
Imagel:Lamotrigine.svg
Imager:Lamotrigine ball-and-stick model.png
Tradename:Lamictal, others
Dailymedid:Lamotrigine
Pregnancy Au:D
Pregnancy Au Comment:[1]
Routes Of Administration:Oral (by mouth)
Class:Phenyltriazine
Atc Prefix:N03
Atc Suffix:AX09
Legal Au:S4
Legal Br:C1
Legal Br Comment:[2]
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Legal Us Comment:[3]
Legal Eu:Rx-only
Legal Eu Comment:[4]
Bioavailability:98%
Protein Bound:55%
Metabolism:Liver (mostly UGT1A4-mediated)
Elimination Half-Life:29 hours
Excretion:Urine (65%), feces (2%)
Cas Number:84057-84-1
Pubchem:3878
Iuphar Ligand:2622
Drugbank:DB00555
Chemspiderid:3741
Unii:U3H27498KS
Kegg:D00354
Chebi:6367
Chembl:741
Synonyms:BW-430C; BW430C; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Iupac Name:6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
C:9
H:7
Cl:2
N:5
Smiles:NC1=NC(N)=NN=C1C2=CC=CC(Cl)=C2Cl
Stdinchi:1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
Stdinchikey:PYZRQGJRPPTADH-UHFFFAOYSA-N

Lamotrigine, sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder.[5] For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome.[5] In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression in any groups except for the severely depressed; but for patients with bipolar disorder who are not currently symptomatic, it appears to reduce the risk of future episodes of depression.[6]

Common side effects include nausea, sleepiness, headache, vomiting, trouble with coordination, and rash.[5] Serious side effects include excessive breakdown of red blood cells, increased risk of suicide, severe skin reaction (Stevens–Johnson syndrome), and allergic reactions, which can be fatal.[5] Lamotrigine is a phenyltriazine, making it chemically different from other anticonvulsants.[5] Its mechanism of action is not clear, but it appears to inhibit release of excitatory neurotransmitters via voltage-sensitive sodium channels and voltage-gated calcium channels in neurons.[5] [7] [8]

Lamotrigine was first marketed in Ireland in 1991, and approved for use in the United States in 1994.[5] [9] It is on the World Health Organization's List of Essential Medicines.[10] In 2021, it was the 50th most commonly prescribed medication in the United States, with more than 13million prescriptions.[11] [12]

Medical uses

Epilepsy

Lamotrigine is considered a first-line drug for primary generalized tonic-clonic seizures (includes simple partial, complex partial, and secondarily generalized seizures such as focal-onset tonic-clonic seizures). It is also used as an alternative or adjuvant medication for partial seizures, such as absence seizure, myoclonic seizure, and atonic seizures.[13] [14] A 2020 review on the use of lamotrigine as an add-on therapy for drug resistant generalized tonic-clonic seizures was unable to come to conclusions to inform clinical practice. Although low-certainty evidence suggest that it reduces generalized tonic-clonic seizures by 50% the level of uncertainty indicates that the actual findings could be significantly different.[15] Another 2020 Cochrane review examining the use of lamotrigine as an add-on therapy for drug-resistant focal epilepsy found it to be effective for reducing seizure frequency and was well tolerated.[16]

Lennox–Gastaut syndrome

Lamotrigine is one of a small number of FDA-approved therapies for the form of epilepsy known as Lennox–Gastaut syndrome.[17] It reduces the frequency of LGS seizures, and is one of two medications known to decrease the severity of drop attacks.[18] Combination with valproate is common, but this increases the risk of lamotrigine-induced severe skin reaction Stevens–Johnson syndrome, and necessitates reduced dosing due to the interaction of these drugs.[19]

Bipolar disorder

Lamotrigine is approved in the US for maintenance treatment of bipolar I disorder and bipolar II disorder.[20] While the anticonvulsants carbamazepine and valproate are predominantly antimanics, lamotrigine has demonstrated efficacy only in preventing or reducing the risk of recurrent depressive episodes of bipolar disorder. The drug seems ineffective in the treatment of current rapid-cycling, acute mania, or acute depression in bipolar disorder.[21] Lamotrigine has been shown to be as effective as lithium, the standard treatment for bipolar disorder.[22]

Lamotrigine has not demonstrated clear efficacy in treating acute mood episodes, either mania or depression. It has not demonstrated effectiveness in treating acute mania,[23] and there is controversy regarding the drug's effectiveness in treating acute bipolar depression.[24] A paper written in 2008 by Nassir et al. reviewed evidence from trials that were unpublished and not referenced in the 2002 APA guidelines, and it concludes that lamotrigine has "very limited, if any, efficacy in the treatment of acute bipolar depression". A 2008 paper by Calabrese et al. examined much of the same data, and found that in five placebo-controlled studies, lamotrigine did not significantly differ from placebo in the treatment of bipolar depression.[25] However, in a meta-analysis of these studies conducted in 2008, Geddes, Calabrese and Goodwin found that lamotrigine was effective in individuals with bipolar depression, with a number needed to treat (NNT) of 11, or 7 in severe depression.[26]

A 2013 review concluded that lamotrigine is recommended in bipolar maintenance when depression is prominent and that more research is needed in regard to its role in the treatment of acute bipolar depression and unipolar depression. No information to recommend its use in other psychiatric disorders was found.[27]

Schizophrenia

Lamotrigine, as a monotherapy, is not substantially effective against schizophrenia. However, various publications[28] [29] and textbooks[30] [31] have expressed that lamotrigine could be added to clozapine as augmentation therapy against partial or non-responding schizophrenic patients. Patients had statistically significant improvements in positive, negative and affective symptoms. Lamotrigine does not have a statistically significant effect with antipsychotics other than clozapine, such as: olanzapine, risperidone, haloperidol, zuclopenthixol, etc.[32]

Other uses

Off-label uses include the treatment of peripheral neuropathy, trigeminal neuralgia, cluster headaches, migraines, visual snow, and reducing neuropathic pain,[33] [34] [35] [36] although a systematic review conducted in 2013 concluded that well-designed clinical trials have shown no benefit for lamotrigine in neuropathic pain.[37] Off-label psychiatric usage includes the treatment of treatment-resistant obsessive-compulsive disorder,[38] depersonalization derealization disorder,[39] hallucinogen persisting perception disorder,[40] schizoaffective disorder,[41] and borderline personality disorder.[42] It has not been shown to be useful in post-traumatic stress disorder.[43]

GlaxoSmithKline investigated lamotrigine for the treatment of ADHD with inconclusive results. No detrimental effects on cognitive function were observed; however, the only statistical improvement in core ADHD symptoms was an improvement on a Paced Auditory Serial Addition Test that measures auditory processing speed and calculation ability.[44] Another study reported that lamotrigine might be a safe and effective treatment option for adult ADHD comorbid with bipolar and recurrent depression.[45]

Side effects

Side effects such as rash, fever, and fatigue are very serious, as they may indicate incipient SJS, TEN, DRESS syndrome, or aseptic meningitis.[46]

Lamotrigine prescribing information has a black box warning about life-threatening skin reactions, including Stevens–Johnson syndrome (SJS), DRESS syndrome, and toxic epidermal necrolysis (TEN). The manufacturer states that nearly all cases appear in the first two to eight weeks of therapy. Patients should seek medical attention for any unexpected skin rash, as its presence is an indication of a possible serious or even deadly side effect of the drug. Not all rashes that occur while taking lamotrigine progress to SJS or TEN. Between 5 and 10% of patients will develop a rash, but only one in a thousand patients will develop a serious rash. Rash and other skin reactions are more common in children, so this medication is often reserved for adults. For patients whose lamotrigine has been stopped after development of a rash, rechallenge with lamotrigine is also a viable option. Usually, rechallenge is done with reinstating lamotrigine at a smaller dose (5mg/day). However, it is not applicable for very serious cases.[47] The incidence of these eruptions increases in patients who are currently on, or recently discontinued a valproate-type anticonvulsant drug, as these medications interact in such a way that the clearance of both is decreased and the effective dose of lamotrigine is increased.

In 2018, the FDA required a new warning for the risk of hemophagocytic lymphohistiocytosis. This serious reaction can occur between days to weeks after starting the treatment.[48]

Other side effects include alopecia (hair loss), loss of balance or coordination, double vision, crossed eyes, pupil constriction, blurred vision, dizziness and lack of coordination, drowsiness, insomnia, anxiety, vivid dreams or nightmares, dry mouth, mouth ulcers, memory problems, mood changes, itchiness, runny nose, cough, nausea, indigestion, abdominal pain, weight loss, missed or painful menstrual periods, and vaginitis. The side-effects profile varies for different patient populations.[46] Overall adverse effects in treatment are similar between men, women, geriatric, pediatric and racial groups.

Lamotrigine has been associated with a decrease in white blood cell count (leukopenia).[49] Lamotrigine does not prolong QT/QTc in TQT studies in healthy subjects.[50]

In people taking antipsychotics, cases of lamotrigine-precipitated neuroleptic malignant syndrome have been reported.[51] [52]

Women

Women are more likely than men to have side effects.

Some evidence shows interactions between lamotrigine and female hormones, which can be of particular concern for women on estrogen-containing hormonal contraceptives. Ethinylestradiol, an ingredient of such contraceptives, has been shown to decrease serum levels of lamotrigine.[53] Women starting an estrogen-containing oral contraceptive may need to increase the dosage of lamotrigine to maintain its level of efficacy. Likewise, women may experience an increase in lamotrigine side effects upon discontinuation of birth control pills. This may include the "pill-free" week where lamotrigine serum levels have been shown to increase twofold.

Pregnancy and breastfeeding

Many studies have found no association between lamotrigine exposure in utero and birth defects, while those that have found an association have found only slight associations with minor malformations such as cleft palates.[54] Review studies have found that overall rates of congenital malformations in infants exposed to lamotrigine in utero are relatively low (1–4%), which is similar to the rate of malformations in the general population.[55] [56] It is known that lamotrigine is a weak inhibitor of human dihydrofolate reductase (DHFR) and other, more powerful, human DHFR inhibitors such as methotrexate are known to be teratogenic.[54]

Lamotrigine is expressed in breast milk; the manufacturer recommends carefully weighing the benefits and risks of taking lamotrigine while breastfeeding.[57] However, some studies suggest that lamotrigine is safe to use while breastfeeding.[58] A frequently updated review of scientific literature rates lamotrigine as L3: moderately safe.[59]

Other types of effects

Lamotrigine binds to melanin-containing tissues such as the iris of the eye or melanin-rich skin. The long-term consequences of this are unknown.[60]

Lamotrigine is known to affect sleep. Studies with small numbers of patients (10–15) reported that lamotrigine increases the duration of REM sleep, decreases the number of phase shifts, and decreases the duration of slow-wave sleep,[61] and that there was no effect on vigilance,[62] daytime somnolence and cognitive function.[63] However, a retrospective study of 109 patients' medical records found that 6.7% of patients experienced an "alerting effect" resulting in intolerable insomnia, for which the treatment had to be discontinued.[64]

Lamotrigine can induce a type of seizure known as a myoclonic jerk, which tends to happen soon after the use of the medication.[65] When used in the treatment of myoclonic epilepsies such as juvenile myoclonic epilepsy, lower doses (and lower plasma levels) are usually needed, as even moderate doses of this drug can induce seizures, including tonic-clonic seizures, which can develop into status epilepticus, which is a medical emergency. It can also cause myoclonic status epilepticus.

In overdose, lamotrigine can cause uncontrolled seizures in most people. Reported results in overdoses involving up to 15 g include increased seizures, coma, and death.

Pharmacology

Mechanism of action

Lamotrigine is a member of the sodium channel blocking class of antiepileptic drugs.[66] This may suppress the release of glutamate and aspartate, two dominant excitatory neurotransmitters in the central nervous system. It is generally accepted to be a member of the sodium channel blocking class of antiepileptic drugs,[67] but it could have additional actions, since it has a broader spectrum of action than other sodium channel antiepileptic drugs such as phenytoin and is effective in the treatment of the depressed phase of bipolar disorder, whereas other sodium channel-blocking antiepileptic drugs are not, possibly on account of its sigma receptor activity. In addition, lamotrigine shares few side effects with other, unrelated anticonvulsants known to inhibit sodium channels, which further emphasizes its unique properties.[68]

It is a triazine derivate that inhibits voltage-sensitive sodium channels, leading to stabilization of neuronal membranes. It also blocks L-, N-, and P-type calcium channels and weakly inhibits the serotonin 5-HT3 receptor.[69] These actions are thought to inhibit release of glutamate at cortical projections in the ventral striatum limbic areas,[70] and its neuroprotective and antiglutamatergic effects have been pointed out as promising contributors to its mood stabilizing activity.[71] Observations that lamotrigine reduced γ-aminobutyric acid (GABA) A receptor-mediated neurotransmission in rat amygdala, suggest that a GABAergic mechanism may also be involved.[72] It appears that lamotrigine does not increase GABA blood levels in humans.[73]

Lamotrigine does not have pronounced effects on any of the usual neurotransmitter receptors that anticonvulsants affect (adrenergic, dopamine D1 and D2, muscarinic, GABA, histaminergic H1, serotonin 5-HT2, and N-methyl-D-aspartate). Inhibitory effects on 5-HT, norepinephrine, and dopamine transporters are weak.[74] Lamotrigine is a weak inhibitor of dihydrofolate reductase,[75] but whether this effect is sufficient to contribute to a mechanism of action or increases risk to the fetus during pregnancy is not known. Early studies of lamotrigine's mechanism of action examined its effects on the release of endogenous amino acids from rat cerebral cortex slices in vitro. As is the case for antiepileptic drugs that act on voltage-dependent sodium channels, lamotrigine thereby inhibits the release of glutamate and aspartate, which is evoked by the sodium-channel activator veratrine, and was less effective in the inhibition of acetylcholine or GABA release. At high concentrations, it had no effect on spontaneous or potassium-evoked amino acid release.

These studies suggested that lamotrigine acts presynaptically on voltage-gated sodium channels to decrease glutamate release. Several electrophysiological studies have investigated the effects of lamotrigine on voltage-gated sodium channels. For example, lamotrigine blocked sustained repetitive firing in cultured mouse spinal cord neurons in a concentration-dependent manner, at concentrations that are therapeutically relevant in the treatment of human seizures. In cultured hippocampal neurons, lamotrigine reduced sodium currents in a voltage-dependent manner, and at depolarised potentials showed a small frequency-dependent inhibition. These and a variety of other results indicate that the antiepileptic effect of lamotrigine, like those of phenytoin and carbamazepine, is at least in part due to use- and voltage-dependent modulation of fast voltage-dependent sodium currents. However, lamotrigine has a broader clinical spectrum of activity than phenytoin and carbamazepine and is recognized to be protective against generalized absence epilepsy and other generalized epilepsy syndromes, including primary generalized tonic–clonic seizures, juvenile myoclonic epilepsy, and Lennox-Gastaut syndrome.

The basis for this broader spectrum of activity of lamotrigine is unknown, but could relate to actions of the drug on voltage-gated calcium channels. Lamotrigine blocks T-type calcium channels weakly, if at all. However, it does inhibit native and recombinant high voltage–gated calcium channels (N- and P/Q/R-types) at therapeutic concentrations. Whether this activity on calcium channels accounts for lamotrigine's broader clinical spectrum of activity in comparison with phenytoin and carbamazepine remains to be determined.

It antagonizes these receptors with the following IC50 values:

Pharmacokinetics

The pharmacokinetics of lamotrigine follow first-order kinetics, with a half-life of 29 hours and volume of distribution of 1.36L/kg.[76] Lamotrigine is rapidly and completely absorbed after oral administration. Its absolute bioavailability is 98% and its plasma Cmax occurs from 1.4 to 4.8 hours. Available data indicate that its bioavailability is not affected by food. Estimate of the mean apparent volume of distribution of lamotrigine following oral administration ranges from 0.9 to 1.3L/kg. This is independent of dose and is similar following single and multiple doses in both patients with epilepsy and in healthy volunteers.[77]

Lamotrigine is inactivated by glucuronidation in the liver.[78] Lamotrigine is metabolized predominantly by glucuronic acid conjugation. Its major metabolite is an inactive 2-n-glucuronide conjugate.[79]

Lamotrigine has fewer drug interactions than many anticonvulsant drugs, although pharmacokinetic interactions with carbamazepine, phenytoin and other hepatic enzyme inducing medications may shorten half-life.[80] Dose adjustments should be made on clinical response, but monitoring may be of benefit in assessing compliance.

The capacity of available tests to detect potentially adverse consequences of melanin binding is unknown. Clinical trials excluded subtle effects and optimal duration of treatment. There are no specific recommendations for periodic ophthalmological monitoring. Lamotrigine binds to the eye and melanin-containing tissues which can accumulate over time and may cause toxicity. Prescribers should be aware of the possibility of long-term ophthalmologic effects and base treatment on clinical response. Patient compliance should be periodically reassessed with lab and medical testing of liver and kidney function to monitor progress or side effects.

Chemistry

The first synthesis of lamotrigine was disclosed in a patent file by the Wellcome Foundation in 1980.[81] [82] 2,3-Dichlorobenzoyl chloride is treated with cuprous cyanide to form an acyl cyanide. This is then reacted with the nitrate salt of aminoguanidine to give an intermediate which is cyclised to the diamino triazine of the drug product.[83]

History

Society and culture

Brand names

Lamotrigine is sold under the original brand name Lamictal and it is available in generic form under many brand names worldwide.[87] [88]

Regulatory advisory in 2021

In March 2021, the United States Food and Drug Administration (FDA) issued a warning regarding the potential for cardiac arrhythmias in people with pre-existing structural or conduction heart defects.[89] [90] The warning provoked consternation and controversy within the professional community.[91] An in-vitro study conducted in 2011 predicted Class IB antiarrhythmic activity at therapeutic concentrations of lamotrigine, due to its sodium channel-blocking activity.[92] Thus, lamotrigine use in at-risk populations could prolong the QRS interval on the electrocardiogram, and increase the risk of arrhythmias and sudden death. No references to human studies or postmarket data in at-risk populations (i.e., people with structural heart disease) were cited to support the warning. A study in dogs is mentioned in the prescribing information brochure by the manufacturer. A rapid systematic review concluded that "there is insufficient evidence to support or refute that lamotrigine is associated with sudden death or electrocardiogram changes..."[93] The FDA has recommended that further studies are conducted with lamotrigine and other sodium-channel blocking antiseizure medications.

In March 2023, a FAERS (FDA Adverse Event Reporting System) analysis demonstrated signals of cardiac arrest, but not of tachyarrhythmia or bradyarrhythmia nor their clinical manifestation as fainting in lamotrigine. The study stratified the epileptic and psychiatric indications, explaining that the nature of the signal for cardiac arrest seems to be confounded by the psychiatric indication, which included 2.5 times more concomitant medications with cardiac adverse events, such as QT-prolonging drugs. Additionally, a 1.5-fold greater reports on overdose and suicide attempts was recorded in the psychiatric reports. Although lamotrigine blocks the cardiac sodium channels at therapeutically relevant concentrations, owing to its short-fast kinetics at the channel level, this blockage did not translate into a disproportional signal in this study.[94]

Research

Though lamotrigine has been used to treat seizures in infants, as of 2023, its effectiveness in this age group has been evaluated in only one study. Adverse effects were rarely severe enough for the medication to be discontinued in this age group, however, its effectiveness in reducing seizures was inconclusive.[95]

Notes and References

  1. Web site: Lamotrigine Use During Pregnancy . Drugs.com . 8 October 2019 . 24 March 2020 . 25 January 2021 . https://web.archive.org/web/20210125224408/https://www.drugs.com/pregnancy/lamotrigine.html . live .
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  3. Web site: Lamictal XR- lamotrigine tablet, film coated, extended release Lamictal XR- lamotrigine kit . DailyMed . 13 April 2022 . 27 August 2022 . 27 August 2022 . https://web.archive.org/web/20220827011250/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e2c9a35-6a39-41d7-ad84-3c0bb8894b09 . live .
  4. Web site: Lamictal . European Medicines Agency . 17 September 2018 . 27 August 2022 . 27 August 2022 . https://web.archive.org/web/20220827012357/https://www.ema.europa.eu/en/medicines/human/referrals/lamictal . live .
  5. Web site: Lamotrigine. The American Society of Health-System Pharmacists. 8 December 2017. 10 December 2017. https://web.archive.org/web/20171210020403/https://www.drugs.com/monograph/lamotrigine.html. live.
  6. Web site: Lamotrigine: Its Role in Bipolar Disorder. 26 November 2019 . PsychiatricTimes. 1 September 2020. 26 January 2021. https://web.archive.org/web/20210126155815/https://www.psychiatrictimes.com/view/lamotrigine-its-role-bipolar-disorder. live.
  7. Web site: Lamotrigine. PubChem Open Chemistry Database. National Institutes of Health. US. 13 December 2016. 6 September 2016. https://web.archive.org/web/20160906142844/http://pubchem.ncbi.nlm.nih.gov/compound/3878#section=Top. live.
  8. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM . Lamotrigine: a review of its use in bipolar disorder . Drugs . 63 . 19 . 2029–2050 . 1 October 2003 . 12962521 . 10.2165/00003495-200363190-00009 . 15 January 2022 . live . https://web.archive.org/web/20220827013339/https://link.springer.com/article/10.2165/00003495-200363190-00009 . 27 August 2022 .
  9. Book: Shorvon SD, Perucca E, Engel J. The Treatment of Epilepsy. John Wiley & Sons, Incorporated. 9781118936993. 1321. 4th. 2015. 31 August 2020. 2 August 2021. https://web.archive.org/web/20210802114654/https://books.google.com/books?id=ppKbCgAAQBAJ&pg=PT1535. live.
  10. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  11. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  12. Web site: Lamotrigine - Drug Usage Statistics . ClinCalc . 14 January 2024 .
  13. Book: Kasper D . Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J . Harrison's Principles of Internal Medicine . 16th . McGraw-Hill. 2005 . 3–22 . 9780071466332. etal.
  14. Book: Tierny LM . McPhee SJ, Papadakis MA . Current Medical Diagnosis and Treatment, 45th ed . McGraw-Hill . 2006 . 978-0071454100 . registration .
  15. Bresnahan R, Panebianco M, Marson AG . Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures . The Cochrane Database of Systematic Reviews . 2020 . 7 . CD007783 . July 2020 . 32609387 . 7387132 . 10.1002/14651858.CD007783.pub3 .
  16. Panebianco M, Bresnahan R, Ramaratnam S, Marson AG . Lamotrigine add-on therapy for drug-resistant focal epilepsy . The Cochrane Database of Systematic Reviews . 2020 . 3 . CD001909 . March 2020 . 32196639 . 7083514 . 10.1002/14651858.CD001909.pub3 .
  17. Brigo F, Jones K, Eltze C, Matricardi S . Anti-seizure medications for Lennox-Gastaut syndrome . The Cochrane Database of Systematic Reviews . 4 . 4 . CD003277 . April 2021 . 33825230 . 8095011 . 10.1002/14651858.CD003277.pub4 .
  18. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA . 6 . Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society . Neurology . 62 . 8 . 1261–1273 . April 2004 . 15111660 . 10.1212/01.WNL.0000123695.22623.32 . 2 April 2005 . live . free . https://web.archive.org/web/20041216010053/http://www.neurology.org/cgi/content/full/62/8/1261 . 16 December 2004 .
  19. Pellock JM . Managing pediatric epilepsy syndromes with new antiepileptic drugs . Pediatrics . 104 . 5 Pt 1 . 1106–1116 . November 1999 . 10545555 . 10.1542/peds.104.5.1106 . 1090325 .
  20. Web site: Lamictal (lamotrigine) Label Information . GlaxoSmithKline . . 12 October 2010 . 5 August 2019 . dead . https://web.archive.org/web/20170420151835/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM235547.pdf . 20 April 2017 .
  21. Nassir Ghaemi S, Shirzadi AA, Filkowski M . Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder . Medscape Journal of Medicine . 10 . 9 . 211 . 2008 . 19008973 . 2580079 .
  22. Hashimoto Y, Kotake K, Watanabe N, Fujiwara T, Sakamoto S . Lamotrigine in the maintenance treatment of bipolar disorder . The Cochrane Database of Systematic Reviews . 2021 . 9 . CD013575 . September 2021 . 34523118 . 8440301 . 10.1002/14651858.CD013575.pub2 .
  23. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM . Lamotrigine: a review of its use in bipolar disorder . Drugs . 63 . 19 . 2029–2050 . 2003 . 12962521 . 10.2165/00003495-200363190-00009 .
  24. Geddes JR, Miklowitz DJ . Treatment of bipolar disorder . Lancet . 381 . 9878 . 1672–1682 . May 2013 . 23663953 . 3876031 . 10.1016/S0140-6736(13)60857-0 .
  25. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA . 6 . Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials . Bipolar Disorders . 10 . 2 . 323–333 . March 2008 . 18271912 . 10.1111/j.1399-5618.2007.00500.x .
  26. Geddes JR, Calabrese JR, Goodwin GM . Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials . The British Journal of Psychiatry . 194 . 1 . 4–9 . January 2009 . 19118318 . 10.1192/bjp.bp.107.048504 . free .
  27. Reid JG, Gitlin MJ, Altshuler LL . Lamotrigine in psychiatric disorders . The Journal of Clinical Psychiatry . 74 . 7 . 675–684 . July 2013 . 23945444 . 10.4088/JCP.12r08046 .
  28. Tiihonen J, Wahlbeck K, Kiviniemi V . The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis . Schizophrenia Research . 109 . 1–3 . 10–14 . April 2009 . 19186030 . 10.1016/j.schres.2009.01.002 . 25302931 .
  29. Dursun SM, McIntosh D, Milliken H . Clozapine plus lamotrigine in treatment-resistant schizophrenia . Archives of General Psychiatry . 56 . 10 . 950 . October 1999 . 10530638 . 10.1001/archpsyc.56.10.950 .
  30. Book: Taylor DM . 2018 . The Maudsley Prescribing Guidelines in Psychiatry . Wiley . Hoboken, NJ . 159 . 9781119442561.
  31. Book: Stahl SM . 2017 . Stahl's Essential Psychopharmacology Prescriber's Guide . 6th . Cambridge University Press . Cambridge . 178 . 9781316618134.
  32. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U . Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia . Biological Psychiatry . 56 . 6 . 441–446 . September 2004 . 15364042 . 10.1016/j.biopsych.2004.06.029 . 7479755 .
  33. Backonja M . Neuromodulating drugs for the symptomatic treatment of neuropathic pain . Current Pain and Headache Reports . 8 . 3 . 212–216 . June 2004 . 15115640 . 10.1007/s11916-004-0054-4 . 24786792 .
  34. Jensen TS . Anticonvulsants in neuropathic pain: rationale and clinical evidence . European Journal of Pain . 6 Suppl A . Suppl A . 61–68 . 2002 . 11888243 . 10.1053/eujp.2001.0324 . 22742865 . free .
  35. Pappagallo M . Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine . Clinical Therapeutics . 25 . 10 . 2506–2538 . October 2003 . 14667954 . 10.1016/S0149-2918(03)80314-4 . 10.1.1.451.9407 .
  36. Bou Ghannam A, Pelak VS . Visual Snow: a Potential Cortical Hyperexcitability Syndrome . Current Treatment Options in Neurology . 19 . 3 . 9 . March 2017 . 28349350 . 10.1007/s11940-017-0448-3 . 4829787 .
  37. Wiffen PJ, Derry S, Moore RA . Lamotrigine for chronic neuropathic pain and fibromyalgia in adults . The Cochrane Database of Systematic Reviews . 2013 . 12 . CD006044 . December 2013 . 24297457 . 6485508 . 10.1002/14651858.CD006044.pub4 .
  38. Hussain A, Dar MA, Wani RA, Shah MS, Jan MM, Malik YA, Chandel RK, Margoob MA . 6 . Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia . Indian Journal of Psychological Medicine . 37 . 2 . 154–158 . 2015 . 25969599 . 4418246 . 10.4103/0253-7176.155613 . free .
  39. Medford N . Understanding and treating depersonalisation disorder . 10.1192/apt.11.2.92 . Advances in Psychiatric Treatment . 11 . 2 . 92–100 . 2005 . free .
  40. Hermle L, Simon M, Ruchsow M, Geppert M . Hallucinogen-persisting perception disorder . Therapeutic Advances in Psychopharmacology . 2 . 5 . 199–205 . October 2012 . 23983976 . 3736944 . 10.1177/2045125312451270 .
  41. Erfurth A, Walden J, Grunze H . Lamotrigine in the treatment of schizoaffective disorder . Neuropsychobiology . 38 . 3 . 204–205 . October 1998 . 9778612 . 10.1159/000026540 . 9 September 2019 . live . 46848204 . https://web.archive.org/web/20210828140506/https://epub.ub.uni-muenchen.de/16560/1/10_1159_000026540.pdf . 28 August 2021 .
  42. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM . Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials . The British Journal of Psychiatry . 196 . 1 . 4–12 . January 2010 . 20044651 . 10.1192/bjp.bp.108.062984 . free .
  43. Williams T, Phillips NJ, Stein DJ, Ipser JC . Pharmacotherapy for post traumatic stress disorder (PTSD) . The Cochrane Database of Systematic Reviews . 2022 . 3 . CD002795 . March 2022 . 35234292 . 8889888 . 10.1002/14651858.CD002795.pub3 .
  44. Web site: Glaxo Smith Klein Clinical Study Register . Study No. LAM40120 . Lamotrigine (Lamictal) Treatment in adults with Attention Deficit Hyperactivity Disorder (ADHD), A pilot study . https://web.archive.org/web/20171201131224/https://www.gsk-clinicalstudyregister.com/files2/1623.pdf . 1 December 2017 .
  45. Öncü B, Er O, Çolak B, Nutt DJ . Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series . Journal of Psychopharmacology . 28 . 3 . 282–283 . March 2014 . 23784736 . 10.1177/0269881113493365 . 8011752 .
  46. Web site: Lamictal (Lamotrigine): Uses, Dosage, Side Effects, Interactions, Warning . 26 August 2016 . 27 August 2016 . https://web.archive.org/web/20160827070255/http://www.rxlist.com/lamictal-drug.htm . live .
  47. Serrani Azcurra DJ . Lamotrigine rechallenge after a skin rash. A combined study of open cases and a meta-analysis . Revista de Psiquiatria y Salud Mental . 6 . 4 . 144–149 . Jun 2012 . 23084805 . 10.1016/j.rpsm.2012.04.002 . 10 December 2019 . live . https://web.archive.org/web/20210828140510/https://zenodo.org/record/895436/preview/article.pdf . 28 August 2021 .
  48. Web site: Safety Alerts for Human Medical Products - Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction. www.fda.gov. 14 May 2018. 25 July 2018. https://web.archive.org/web/20180725121507/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm605628.htm. dead.
  49. Nicholson RJ, Kelly KP, Grant IS . Leucopenia associated with lamotrigine . BMJ . 310 . 6978 . 504 . February 1995 . 7888892 . 2548879 . 10.1136/bmj.310.6978.504b .
  50. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, Lorch U, Taubel J . 6 . Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects . British Journal of Clinical Pharmacology . 66 . 3 . 396–404 . September 2008 . 18662287 . 2526242 . 10.1111/j.1365-2125.2008.03250.x . https://web.archive.org/web/20170809114208/http://www.richmondpharmacology.com/downloads/Publications/Lamotrigine%20does%20not%20prolong%20QTc%20in%20a%20thorough%20QTQTc%20study%20in%20healthy%20subjects.pdf . 9 August 2017 .
  51. Motomura E, Tanii H, Usami A, Ohoyama K, Nakagawa M, Okada M . Lamotrigine-induced neuroleptic malignant syndrome under risperidone treatment: a case report . The Journal of Neuropsychiatry and Clinical Neurosciences . 24 . 2 . E38–E39 . March 2012 . 22772697 . 10.1176/appi.neuropsych.11040093 .
  52. Ishioka M, Yasui-Furukori N, Hashimoto K, Sugawara N . Neuroleptic malignant syndrome induced by lamotrigine . Clinical Neuropharmacology . 36 . 4 . 131–132 . July–August 2013 . 23783003 . 10.1097/WNF.0b013e318294799a . 19508393 .
  53. Reimers A, Helde G, Brodtkorb E . Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations . Epilepsia . 46 . 9 . 1414–1417 . September 2005 . 16146436 . 10.1111/j.1528-1167.2005.10105.x . 7408965 . free .
  54. Web site: Product Information Lamotrigine Sandoz 25mg, 50mg, 100mg, 200mg, Dispersible/Chewable Tablets. TGA eBusiness Services. Sandoz Pty Ltd. 10 January 2017. 23 August 2017. 23 August 2017. https://web.archive.org/web/20170823204339/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-02602-1. live.
  55. Berwaerts K, Sienaert P, De Fruyt J . [Teratogenic effects of lamotrigine in women with bipolar disorder] . nl . Tijdschrift voor Psychiatrie . 51 . 10 . 741–750 . 2009 . 19821242 .
  56. Prabhu LV, Nasar MA, Rai R, Madhyastha S, Singh G . Lamotrigine in pregnancy: safety profile and the risk of malformations . Singapore Medical Journal . 48 . 10 . 880–883 . October 2007 . 17909669 .
  57. Web site: February 2023 . Prescribing information, Lamictal . 25 April 2023 . GSK . en . 23 March 2023 . https://web.archive.org/web/20230323052319/https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF . live .
  58. Dalili H, Nayeri F, Shariat M, Asgarzadeh L . Lamotrigine effects on breastfed infants . Acta Medica Iranica . 53 . 7 . 393–394 . July 2015 . 26520624 .
  59. Book: Medications and Mothers' Milk . Hale TW . 2008 . Hale Publishing. 978-0-9815257-2-3 . 532 . 13th.
  60. Web site: Lamictal, Warnings & Precautions . RxList Inc.. 2 November 2020. 29 June 2021. https://web.archive.org/web/20210629110648/https://www.rxlist.com/lamictal-drug.htm#warnings. live.
  61. Foldvary N, Perry M, Lee J, Dinner D, Morris HH . The effects of lamotrigine on sleep in patients with epilepsy . Epilepsia . 42 . 12 . 1569–1573 . December 2001 . 11879368 . 10.1046/j.1528-1157.2001.46100.x . 12218913 . free .
  62. Bonanni E, Galli R, Gori S, Pasquali L, Maestri M, Iudice A, Murri L . Neurophysiological evaluation of vigilance in epileptic patients on monotherapy with lamotrigine . Clinical Neurophysiology . 112 . 6 . 1018–1022 . June 2001 . 11377260 . 10.1016/S1388-2457(01)00537-5 . 6983433 . 11568/186375 .
  63. Placidi F, Marciani MG, Diomedi M, Scalise A, Pauri F, Giacomini P, Gigli GL . Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy . Acta Neurologica Scandinavica . 102 . 2 . 81–86 . August 2000 . 10949523 . 10.1034/j.1600-0404.2000.102002081.x . 24323287 .
  64. Sadler M . Lamotrigine associated with insomnia . Epilepsia . 40 . 3 . 322–325 . March 1999 . 10080513 . 10.1111/j.1528-1157.1999.tb00712.x . 43902298 . free .
  65. Web site: Review: could Lamictal cause Myoclonic jerks? . eHealthMe . 2016 . https://web.archive.org/web/20160129020525/http://www.ehealthme.com/ds/lamictal/myoclonic+jerks . 29 January 2016 .
  66. Book: Rogawski M . Levy RH, Mattson RH, Meldrum BS, Perucca E . Antiepileptic Drugs, Fifth Edition. Lippincott Williams & Wilkins . 2002 . 3–22 . Chapter 1: Principles of antiepileptic drug action . 9780781723213.
  67. Rogawski MA, Löscher W . The neurobiology of antiepileptic drugs . Nature Reviews. Neuroscience . 5 . 7 . 553–564 . July 2004 . 15208697 . 10.1038/nrn1430 . 31 August 2020 . live . 2201038 . https://web.archive.org/web/20201216114030/https://zenodo.org/record/1233562 . 16 December 2020 .
  68. Lees G, Leach MJ . Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex . Brain Research . 612 . 1–2 . 190–199 . May 1993 . 7687190 . 10.1016/0006-8993(93)91660-K . 20535234 .
  69. Web site: Prescribing Information for LAMICTAL (lamotrigine). FDA. 12 January 2020. 12 January 2020. https://web.archive.org/web/20200112201226/https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020241s10s21s25s26s27,020764s3s14s18s19s20lbl.pdf. live.
  70. Thomas SP, Nandhra HS, Jayaraman A . Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD) . Journal of Mental Health . 19 . 2 . 168–175 . April 2010 . 20433324 . 10.3109/09638230903469269 . 39871557 .
  71. Ketter TA, Manji HK, Post RM . Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders . Journal of Clinical Psychopharmacology . 23 . 5 . 484–495 . October 2003 . 14520126 . 10.1097/01.jcp.0000088915.02635.e8 . 35902870 .
  72. Braga MF, Aroniadou-Anderjaska V, Post RM, Li H . Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders . Neuropharmacology . 42 . 4 . 522–529 . March 2002 . 11955522 . 10.1016/s0028-3908(01)00198-8 . 26174058 .
  73. Shiah IS, Yatham LN, Gau YC, Baker GB . Effect of lamotrigine on plasma GABA levels in healthy humans . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 27 . 3 . 419–423 . May 2003 . 12691776 . 10.1016/S0278-5846(03)00028-9 . 19209195 .
  74. Southam E, Kirkby D, Higgins GA, Hagan RM . Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats . European Journal of Pharmacology . 358 . 1 . 19–24 . September 1998 . 9809864 . 10.1016/s0014-2999(98)00580-9 .
  75. Web site: Lamictal- lamotrigine tablet Lamictal- lamotrigine tablet, for suspension Lamictal ODT- lamotrigine tablet, orally disintegrating Lamictal- lamotrigine kit . DailyMed . 13 April 2022 . 27 August 2022 . 27 August 2022 . https://web.archive.org/web/20220827011235/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678 . live .
  76. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, Lai AA, Hubbell J, Chern WH, Allsup T . 6 . Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy . Epilepsy Research . 10 . 2–3 . 191–200 . 1991 . 1817959 . 10.1016/0920-1211(91)90012-5 . 34525226 .
  77. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW . Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans . Clinical Pharmacology and Therapeutics . 42 . 5 . 535–541 . November 1987 . 3677542 . 10.1038/clpt.1987.193 . 19710948 .
  78. Werz MA . Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release . Therapeutics and Clinical Risk Management . 4 . 5 . 1035–1046 . October 2008 . 19209284 . 2621406 . 10.2147/TCRM.S3343 . free .
  79. Goa KL, Ross SR, Chrisp P . Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy . Drugs . 46 . 1 . 152–176 . July 1993 . 7691504 . 10.2165/00003495-199346010-00009 .
  80. Anderson GD . A mechanistic approach to antiepileptic drug interactions . The Annals of Pharmacotherapy . 32 . 5 . 554–563 . May 1998 . 9606477 . 10.1345/aph.17332 . 43441971 .
  81. CA . 1112643 . patent . 1981-11-17 . 1980-05-30 . 1981-03-16 . Baxter MG, Sawyer DA, Miller AA, Elphick AR . 3,5-diamino-6-phenyl-1,2,4-triazines . Wellcome Foundation Ltd .
  82. 10.1021/acs.oprd.7b00262 . An Evaluation of Multiple Catalytic Systems for the Cyanation of 2,3-Dichlorobenzoyl Chloride: Application to the Synthesis of Lamotrigine . 2017 . Leitch DC, John MP, Slavin PA, Searle AD . Organic Process Research & Development . 21 . 11 . 1815–1821 .
  83. Kitson PJ, Marie G, Francoia JP, Zalesskiy SS, Sigerson RC, Mathieson JS, Cronin L . Digitization of multistep organic synthesis in reactionware for on-demand pharmaceuticals . Science . 359 . 6373 . 314–319 . January 2018 . 29348235 . 10.1126/science.aao3466 . 21 April 2023 . live . 206663094 . 2018Sci...359..314K . https://web.archive.org/web/20230421120743/http://eprints.gla.ac.uk/156447/1/156447.pdf . 21 April 2023 .
  84. Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G . Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence . Journal of Affective Disorders . 108 . 1–2 . 1–9 . May 2008 . 18001843 . 10.1016/j.jad.2007.09.012 .
  85. Book: Engel J . Seizures and Epilepsy . 2013 . OUP USA . 9780195328547 . 567 . 31 August 2020 . 2 August 2021 . https://web.archive.org/web/20210802113953/https://books.google.com/books?id=5PgjmjugIX8C&pg=PA567 . live .
  86. Web site: EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003. 19 March 2004. FDA/Center for Drug Evaluation and Research. 9 April 2008. 21 February 2008. https://web.archive.org/web/20080221185906/http://www.fda.gov/cder/rdmt/ESCY03AP.HTM. dead.
  87. Web site: Lamotrigine. Drugs.com. 9 December 2017. 10 December 2017. https://web.archive.org/web/20171210072144/https://www.drugs.com/international/lamotrigine.html. live.
  88. Web site: Treatment for epilepsy: generic lamotrigine. http://webarchive.nationalarchives.gov.uk/20120524031414/http://www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Prescriptions/DH_4104966. 24 May 2012. . 2 March 2005. Department of Health (UK). 9 April 2008.
  89. Web site: Lamictal Prescribing Information . 25 October 2022 . GlaxoSmithKline . 2021 . 26 October 2022 . https://web.archive.org/web/20221026033218/https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF . live .
  90. News: 20 January 2022 . Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease . FDA Drug Safety Podcast . 25 October 2022 . 26 October 2022 . https://web.archive.org/web/20221026033216/https://www.fda.gov/drugs/fda-drug-safety-podcasts/studies-show-increased-risk-heart-rhythm-problems-seizure-and-mental-health-medicine-lamotrigine . live .
  91. Auerbach DS, Muniz CF . Cardiac Safety of Lamotrigine: Still Awaiting a Verdict . Neurology . 98 . 17 . 697–698 . April 2022 . 35260441 . 10.1212/WNL.0000000000200189 . 247316861 .
  92. Harmer AR, Valentin JP, Pollard CE . On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex . British Journal of Pharmacology . 164 . 2 . 260–273 . September 2011 . 21480866 . 3174407 . 10.1111/j.1476-5381.2011.01415.x .
  93. Bunschoten JW, Husein N, Devinsky O, French JA, Sander JW, Thijs RD, Keezer MR . Sudden Death and Cardiac Arrythmia With Lamotrigine: A Rapid Systematic Review . Neurology . 98 . 17 . e1748–e1760 . April 2022 . 35260442 . 10.1212/WNL.0000000000200164 . 247317933 .
  94. Aboukaoud M, Wilf-Yarkoni A, Maor E . Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis . Epilepsia . 64 . 9 . 2322–2329 . September 2023 . 37350356 . 10.1111/epi.17696 . 259231884 . free .
  95. Treadwell JR, Wu M, Tsou AY . Management of Infantile Epilepsies [Internet]. ]. Rockville (MD) . Agency for Healthcare Research and Quality (US) . October 2022 . Report No.: 22(23)-EHC004 2021-SR-01 . 12 July 2023 . 10.23970/ahrqepccer252 . 36383706 . 254357105 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lamotrigine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.